Artelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th

Rhea-AI Summary

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company, announced its invitation to present at the 2022 Virtual Growth Conference on March 28-30, hosted by Maxim Group LLC and M-Vest. The event will feature company presentations, including updates from CEO Gregory Gorgas. Attendees must register as M-Vest members to participate. Artelo focuses on developing therapeutics that target lipid-signaling pathways and the endocannabinoid system, aiming to address significant medical needs in areas like anorexia, cancer, PTSD, and pain management.

SOLANA BEACH, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced it has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

The conference will feature roundtable discussions, fireside chats, and multiple company presentations, including a corporate update from Gregory Gorgas, President and CEO, Artelo Biosciences. Also during this virtual conference, investors will hear from other biotech executives and leaders from a wide range of sectors. Those who wish to attend must first sign up to become an M-Vest member.

Sign up here to access the presentation.

About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven pharmaceutical executives collaborating with highly respected researchers and technology experts, Artelo applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to Artelo’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in Artelo’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. Artelo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com

FAQ

What is Artelo Biosciences presenting at the 2022 Virtual Growth Conference?

Artelo Biosciences will present updates on its therapeutics targeting lipid-signaling pathways at the conference from March 28-30, 2022.

When will the 2022 Virtual Growth Conference take place for Artelo Biosciences?

The conference will be held from March 28 to March 30, 2022.

Who will represent Artelo Biosciences at the 2022 Virtual Growth Conference?

Gregory Gorgas, the President and CEO, will present a corporate update during the conference.

How can investors attend the Virtual Growth Conference featuring Artelo Biosciences?

Investors need to sign up as M-Vest members to attend the conference.

What is the focus of Artelo Biosciences' product development?

Artelo focuses on developing therapeutics that modulate lipid-signaling pathways, addressing conditions like anorexia, cancer, PTSD, pain, and inflammation.